David Chiswell has been appointed chief executive of Kymab Ltd, the antibody development company, having served as interim CEO since early 2015. Dr Chiswell is a co-founder and former CEO of Cambridge Antibody Technology which is now part of AstraZeneca Plc. He is currently chairman of Albireo Pharma AB of Sweden and a director of Nabriva Therapeutics AG, a Vienna, Austria developer of antibiotics.
The appointment was announced on 17 March 2016.
Copyright 2016 Evernow Publishing Ltd